SRF Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Los beneficios de SRF han disminuido a una tasa media anual de -2.8%, mientras que en la industria Chemicals los beneficios crecieron en un 6.1% anualmente. Los ingresos han ido creciendo a una tasa media de 7.5% al año. La rentabilidad financiera de SRF es de 13.1%, y sus márgenes netos son de 11.6%.
Información clave
-2.82%
Tasa de crecimiento de los beneficios
-2.98%
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | 17.68% |
| Tasa de crecimiento de los ingresos | 7.54% |
| Rentabilidad financiera | 13.07% |
| Margen neto | 11.63% |
| Última actualización de beneficios | 31 Mar 2026 |
Actualizaciones de resultados anteriores recientes
Recent updates
Actualización de narrativa • Jun 06
503806: Expanded Capital Outlay Will Support Long Term Performance
Analysts have revised their price target for SRF to ₹3,579 from ₹3,841, citing updated assumptions for revenue growth, profit margins, and the discount rate, while keeping the future P/E expectation broadly similar. What's in the News SRF has scheduled a board meeting on May 5, 2026 to consider and approve the audited financial results for the quarter and year ended March 31, 2026.
Actualización de narrativa • May 22
503806: Expanded Capital Outlay And Dividend Potential Will Support Future Upside
Analysts have trimmed their fair value estimate for SRF from about ₹3,155.83 to ₹2,990.35, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Board meeting scheduled for May 5, 2026, to consider and approve audited financial results for the quarter and year ended March 31, 2026 (company filing).
Actualización de narrativa • Apr 30
503806: Future P/E Compression Will Likely Cap Upside Despite Margin Support
The analyst price target for SRF has been adjusted from ₹2,249.74 to ₹2,200.00 as analysts factor in updated assumptions on discount rate, revenue growth, profit margin and future P/E. What's in the News SRF has scheduled a board meeting on May 05, 2026 to consider and approve the audited financial results for the quarter and year ended March 31, 2026 (company filing).Actualización de narrativa • Apr 08
503806: Fair View As Higher Margins Offset Lower Future P/E Multiple
Analysts have raised their fair value estimate for SRF slightly, from ₹2,239.45 to ₹2,249.74. This reflects updated assumptions for revenue growth, profit margins, a lower assumed discount rate, and a reduced future P/E multiple.Actualización de narrativa • Mar 24
503806: Elevated P E And Margins Will Likely Restrain Future Returns
Analysts have modestly increased their fair value estimate for SRF from ₹2,218.36 to ₹2,239.45, citing updated assumptions regarding revenue growth, profit margins, the discount rate, and future P/E, which together support a slightly higher price target. What's in the News SRF's board approved the appointment of Mr. Samir Kashyap as Chief Financial Officer, effective January 27, 2026.Actualización de narrativa • Mar 09
503806: Elevated P E And Modest Margins Will Likely Restrain Future Returns
Analysts now set their fair value estimate for SRF at ₹2,218, compared with the previous ₹2,244. This reflects updated assumptions around discount rate, revenue growth, profit margins and future P/E expectations.Actualización de narrativa • Feb 23
503806: Elevated P E And Modest Margin Outlook Will Likely Pressure Returns
Analysts have slightly raised their price target on SRF to ₹2,244, citing updated assumptions for the discount rate, revenue growth, profit margin and future P/E. These changes keep their fair value view broadly unchanged in headline terms but reflect a modestly adjusted risk and earnings profile.Actualización de narrativa • Feb 09
503806: Lower Margins And Rich P E Will Likely Pressure Returns
Analysts have raised their price target on SRF to ₹2,244 from ₹2,213, citing updated assumptions on the discount rate, revenue growth, profit margins and a higher future P/E multiple. What's in the News The board has approved the appointment of Mr. Samir Kashyap as Chief Financial Officer, effective January 27, 2026.Actualización de narrativa • Jan 24
503806: New Pharma Plant And CFO Appointment Will Support Future Upside
Analysts have trimmed their price target on SRF to ₹3,155.83 from ₹3,183.00, reflecting slightly more conservative assumptions on revenue growth, profit margin and future P/E, as well as a marginally higher discount rate. What's in the News Board meeting on January 20, 2026 to review unaudited financial results for the quarter and nine months ended December 31, 2025, consider a new pharma intermediate plant project, and discuss a second interim dividend for FY 2025-26 (company filing).Actualización de narrativa • Jan 10
503806: Future Capacity Expansion And CFO Transition Will Support Long Term Prospects
Analysts have kept their fair value estimate for SRF steady at ₹3,841, with only small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that feed into the updated target. This signals broadly consistent expectations compared with prior research.Actualización de narrativa • Dec 26
503806: Future Specialty Fluoropolymer Capacity Expansion May Support Long Term Profitability
Analysts have modestly raised their price target on SRF to a new level, in line with incremental improvements in projected revenue growth, profit margins, and a slightly lower future valuation multiple, signaling a cautiously stronger outlook for the stock. What's in the News Chief Financial Officer Rahul Jain will step down from his role at the close of business on 12 December 2025, with SRF initiating the process to identify a successor and ensure a smooth transition (Key Developments).Actualización de narrativa • Dec 12
503806: Lower Discount Rate May Support Stronger Long Term Profitability
Analysts have raised their fair value estimate for SRF by approximately $191 to $3,841 per share, citing a modestly lower discount rate and slightly higher long term profit margin expectations that more than offset a small reduction in projected revenue growth. What's in the News Chief Financial Officer Rahul Jain will step down from his role at the close of business on 12 December 2025.Actualización de narrativa • Nov 27
503806: CFO Transition And New Facility Approval Will Drive Upside Ahead
Analysts have adjusted their price target for SRF slightly upward from $3,182.93 to $3,183.00, citing minor changes in underlying financial assumptions such as discount rate and projected margin. What's in the News Chief Financial Officer Rahul Jain will step down at the close of business on December 12, 2025.Actualización de narrativa • Nov 12
503806: Upcoming CFO Departure And Facility Decision Will Shape Outlook
Analysts have raised their price target for SRF from $3,138.07 to $3,182.93, citing updated forecasts that reflect slight adjustments in growth and profitability assumptions. What's in the News SRF Limited's Chief Financial Officer, Rahul Jain, announced he will step down from his position at the close of business on December 12, 2025.Actualización de narrativa • Oct 29
New Facility And Supply Chain Moves Will Drive Balanced Opportunity Ahead
Analysts have slightly raised their price target for SRF from $3,137.83 to $3,138.07, citing improved profit margin projections as well as a modest increase in anticipated revenue growth. What's in the News SRF Limited will hold a Board Meeting on October 27, 2025, to consider and approve the un-audited financial results for the quarter and half year ended September 30, 2025.Actualización de narrativa • Oct 15
Sustainability And Capacity Upgrades Will Transform Specialty Chemicals
Analysts have increased their price target for SRF from $3,104.79 to $3,137.83, reflecting updated expectations for the company's financial outlook. What's in the News The Chemours Company and SRF Limited have signed strategic agreements to enhance the global supply chain for fluoropolymers and fluoroelastomers (Key Developments).Actualización de narrativa • Sep 05
Sustainability And Capacity Upgrades Will Transform Specialty Chemicals
With no meaningful change in either the discount rate or forward P/E multiple, analysts have maintained SRF's fair value estimate at ₹3105. What's in the News SRF Limited has entered into strategic agreements with The Chemours Company to strengthen Chemours' global supply chain for fluoropolymers and fluoroelastomers, leveraging SRF's manufacturing capabilities.
Nueva narrativa • Nov 28
Specialty Chemicals Innovations And Global Demand Empower Revenue Growth Journey
SRF's Specialty Chemicals growth and increased production should drive revenue and improve margins due to new product launches and efficiency gains.Desglose de ingresos y gastos
Desglose de ingresos y gastos
Cómo gana y gasta dinero SRF. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 26 | 157,865 | 18,352 | 12,109 | 0 |
| 31 Dec 25 | 154,847 | 17,792 | 11,548 | 0 |
| 30 Sep 25 | 152,635 | 16,176 | 11,347 | 0 |
| 30 Jun 25 | 150,476 | 14,309 | 11,110 | 0 |
| 31 Mar 25 | 146,931 | 12,508 | 10,859 | 0 |
| 31 Dec 24 | 139,495 | 11,469 | 10,547 | 0 |
| 30 Sep 24 | 135,112 | 11,293 | 10,378 | 0 |
| 30 Jun 24 | 132,643 | 12,286 | 10,110 | 0 |
| 31 Mar 24 | 131,385 | 13,357 | 9,768 | 0 |
| 31 Dec 23 | 133,469 | 14,760 | 9,422 | 0 |
| 30 Sep 23 | 137,635 | 17,334 | 9,086 | 0 |
| 30 Jun 23 | 143,139 | 19,136 | 8,772 | 0 |
| 31 Mar 23 | 148,703 | 21,623 | 8,535 | 0 |
| 31 Dec 22 | 146,416 | 22,055 | 8,435 | 0 |
| 30 Sep 22 | 145,178 | 22,002 | 8,401 | 0 |
| 30 Jun 22 | 136,290 | 21,016 | 8,226 | 0 |
| 31 Mar 22 | 124,337 | 18,889 | 8,104 | 0 |
| 31 Dec 21 | 114,919 | 16,647 | 7,597 | 0 |
| 30 Sep 21 | 102,924 | 14,834 | 7,108 | 0 |
| 30 Jun 21 | 95,543 | 14,167 | 6,659 | 0 |
| 31 Mar 21 | 84,000 | 11,983 | 6,393 | 0 |
| 31 Dec 20 | 76,502 | 10,110 | 6,079 | 0 |
| 30 Sep 20 | 73,543 | 10,322 | 5,868 | 0 |
| 30 Jun 20 | 69,913 | 9,174 | 5,652 | 0 |
| 31 Mar 20 | 72,094 | 9,159 | 5,567 | 0 |
| 31 Dec 19 | 78,817 | 9,511 | 6,060 | 0 |
| 30 Sep 19 | 78,411 | 7,592 | 5,862 | 0 |
| 30 Jun 19 | 71,216 | 6,331 | 4,993 | 0 |
| 31 Mar 19 | 70,996 | 5,916 | 4,901 | 0 |
| 31 Dec 18 | 72,329 | 5,747 | 5,306 | 0 |
| 30 Sep 18 | 66,660 | 5,402 | 5,199 | 0 |
| 30 Jun 18 | 60,370 | 4,917 | 4,777 | 0 |
| 31 Mar 18 | 55,890 | 4,617 | 5,035 | 0 |
| 31 Dec 17 | 53,026 | 4,670 | 4,951 | 0 |
| 30 Sep 17 | 50,385 | 4,442 | 4,827 | 0 |
| 30 Jun 17 | 48,952 | 4,642 | 4,465 | 0 |
| 31 Mar 17 | 48,218 | 5,150 | 4,585 | 0 |
| 31 Dec 16 | 45,833 | 4,787 | 4,491 | 0 |
| 30 Sep 16 | 45,459 | 4,709 | 4,363 | 0 |
| 30 Jun 16 | 45,980 | 4,537 | 4,016 | 0 |
| 31 Mar 16 | 45,927 | 4,299 | 4,094 | 0 |
| 31 Dec 15 | 45,353 | 3,746 | 5,788 | 0 |
| 30 Sep 15 | 45,511 | 3,453 | 5,722 | 0 |
| 30 Jun 15 | 45,759 | 3,235 | 5,701 | 0 |
Ingresos de calidad: 503806 tiene ganancias de alta calidad.
Margen de beneficios creciente: Los actuales márgenes de beneficio (11.6%) de 503806 son superiores a los del año pasado (8.5%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de 503806 han disminuido en un 2.8% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de 503806 en el último año (46.7%) supera su media de 5 años (-2.8% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de 503806 en el último año (46.7%) superó al de la industria Chemicals 12.6%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de 503806 (13.1%) se considera baja.
Rentabilidad económica
Rendimiento del capital invertido
Descubre empresas con buenos resultados en el pasado
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/10 18:02 |
| Precio de las acciones al final del día | 2026/06/10 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
SRF Limited está cubierta por 42 analistas. 30 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Kumar Saumya Singh | Ambit Capital |
| Nitin Bhasin | Ambit Capital |